These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 36878698)

  • 1. Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist.
    Alcolea D; Beeri MS; Rojas JC; Gardner RC; Lleó A
    Neurology; 2023 Jul; 101(4):172-180. PubMed ID: 36878698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers for neurodegenerative diseases.
    Hansson O
    Nat Med; 2021 Jun; 27(6):954-963. PubMed ID: 34083813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic Performance and Clinical Applicability of Blood-Based Biomarkers in a Prospective Memory Clinic Cohort.
    Sarto J; Ruiz-García R; Guillén N; Ramos-Campoy Ó; Falgàs N; Esteller D; Contador J; Fernández G; González Y; Tort-Merino A; Juncà-Parella J; Bosch B; Borrego-Écija S; Molina-Porcel L; Castellví M; Vergara M; Antonell A; Augé JM; Naranjo L; Sanchez-Valle R; Lladó A; Balasa M
    Neurology; 2023 Feb; 100(8):e860-e873. PubMed ID: 36450604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood biomarkers of neuronal injury in paediatric cerebral malaria and severe malarial anaemia.
    Datta D; Gopinadhan A; Soto A; Bangirana P; Opoka RO; Conroy AL; Saykin AJ; Kawata K; John CC
    Brain Commun; 2023; 5(6):fcad323. PubMed ID: 38075948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau, Glial Fibrillary Acidic Protein, and Neurofilament Light Chain as Brain Protein Biomarkers in Cerebrospinal Fluid and Blood for Diagnosis of Neurobiological Diseases.
    Park Y; Kc N; Paneque A; Cole PD
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases.
    Sengupta U; Kayed R
    Prog Neurobiol; 2022 Jul; 214():102270. PubMed ID: 35447272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial.
    Pontecorvo MJ; Lu M; Burnham SC; Schade AE; Dage JL; Shcherbinin S; Collins EC; Sims JR; Mintun MA
    JAMA Neurol; 2022 Dec; 79(12):1250-1259. PubMed ID: 36251300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Utility of Cerebrospinal Fluid Biomarkers in Patients with Rapidly Progressive Dementia.
    Kuchenbecker LA; Tipton PW; Martens Y; Brier MR; Satyadev N; Dunham SR; Lazar EB; Dacquel MV; Henson RL; Bu G; Geschwind MD; Morris JC; Schindler SE; Herries E; Graff-Radford NR; Day GS
    Ann Neurol; 2024 Feb; 95(2):299-313. PubMed ID: 37897306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration.
    Gonzalez-Ortiz F; Turton M; Kac PR; Smirnov D; Premi E; Ghidoni R; Benussi L; Cantoni V; Saraceno C; Rivolta J; Ashton NJ; Borroni B; Galasko D; Harrison P; Zetterberg H; Blennow K; Karikari TK
    Brain; 2023 Mar; 146(3):1152-1165. PubMed ID: 36572122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.
    Palmqvist S; Janelidze S; Quiroz YT; Zetterberg H; Lopera F; Stomrud E; Su Y; Chen Y; Serrano GE; Leuzy A; Mattsson-Carlgren N; Strandberg O; Smith R; Villegas A; Sepulveda-Falla D; Chai X; Proctor NK; Beach TG; Blennow K; Dage JL; Reiman EM; Hansson O
    JAMA; 2020 Aug; 324(8):772-781. PubMed ID: 32722745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applying fluid biomarkers to Alzheimer's disease.
    Zetterberg H
    Am J Physiol Cell Physiol; 2017 Jul; 313(1):C3-C10. PubMed ID: 28424166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: Results from the Ontario Neurodegenerative Disease Research Initiative.
    Sanchez E; Wilkinson T; Coughlan G; Mirza S; Baril AA; Ramirez J; Binns MA; Black SE; Borrie M; Dilliott AA; Dixon RA; Dowlatshahi D; Farhan S; Finger E; Fischer CE; Frank A; Freedman M; Goncalves RA; Grimes DA; Hassan A; Hegele RA; Kumar S; Lang AE; Marras C; McLaughlin PM; Orange JB; Pasternak SH; Pollock BG; Rajji TK; Roberts AC; Robinson JF; Rogaeva E; Sahlas DJ; Saposnik G; Strong MJ; Swartz RH; Tang-Wai DF; Tartaglia MC; Troyer AK; Kvartsberg H; Zetterberg H; Munoz DP; ; Masellis M
    Alzheimers Dement; 2024 Mar; 20(3):1753-1770. PubMed ID: 38105605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Biomarkers of Neuronal Injury in Epilepsy Shared with Neurodegenerative Diseases.
    Negi D; Granak S; Shorter S; O'Leary VB; Rektor I; Ovsepian SV
    Neurotherapeutics; 2023 Apr; 20(3):767-778. PubMed ID: 36884195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subjective cognitive complaints and blood biomarkers of neurodegenerative diseases: a longitudinal cohort study.
    Perna L; Stocker H; Burow L; Beyer L; Trares K; Kurz C; Gürsel S; Holleczek B; Tatò M; Beyreuther K; Mons U; Gerwert K; Perneczky R; Schöttker B; Brenner H
    Alzheimers Res Ther; 2023 Nov; 15(1):198. PubMed ID: 37951931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg.
    Obrocki P; Khatun A; Ness D; Senkevich K; Hanrieder J; Capraro F; Mattsson N; Andreasson U; Portelius E; Ashton NJ; Blennow K; Schöll M; Paterson RW; Schott JM; Zetterberg H
    Alzheimers Res Ther; 2020 Feb; 12(1):20. PubMed ID: 32111242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson disease: PD biomarkers-use of α-synuclein reaches new levels.
    Montine TJ
    Nat Rev Neurol; 2011 May; 7(6):308-9. PubMed ID: 21556033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies.
    Mattsson-Carlgren N; Palmqvist S; Blennow K; Hansson O
    Nat Commun; 2020 Dec; 11(1):6252. PubMed ID: 33288742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathologic and cognitive correlates of plasma biomarkers in neurodegenerative disease.
    Cousins KAQ; Phillips JS; Das SR; O'Brien K; Tropea TF; Chen-Plotkin A; Shaw LM; Nasrallah IM; Mechanic-Hamilton D; McMillan CT; Irwin DJ; Lee EB; Wolk DA
    Alzheimers Dement; 2024 Jun; 20(6):3889-3905. PubMed ID: 38644682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alzheimer's and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline.
    Dark HE; An Y; Duggan MR; Joynes C; Davatzikos C; Erus G; Lewis A; Moghekar AR; Resnick SM; Walker KA
    Alzheimers Res Ther; 2024 Apr; 16(1):94. PubMed ID: 38689358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders.
    Ashton NJ; Hye A; Rajkumar AP; Leuzy A; Snowden S; Suárez-Calvet M; Karikari TK; Schöll M; La Joie R; Rabinovici GD; Höglund K; Ballard C; Hortobágyi T; Svenningsson P; Blennow K; Zetterberg H; Aarsland D
    Nat Rev Neurol; 2020 May; 16(5):265-284. PubMed ID: 32322100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.